RT Journal Article
T1 Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
A1 Yadav, Monika
A1 Guzmán Aránguez, Ana Isabel
A1 Pérez de Lara, María Jesús
A1 Singh, Mandeep
A1 Singh, Joga
A1 Kaur, Indu Pal
AB Primary treatment for glaucoma relies on chronic instillation (daily) of intraocular pressure (IOP) lowering eye drops. Present study tends to  develop and assess a novel sustained release bimatoprost loaded nanovesicular (BMT-NV) - thermosensitive in-situ gelling implant (BMT-NV- GEL-IM), for subconjunctival delivery. BMT-NVs developed using novel  composition and method of preparation, (IPA/700/DEL/2014) and industrially viable methodology were characterized and evaluated comprehensively for  ocular suitability. Their incorporation into an in-situ gelling formula was  safe (in vitro and in vivo) and stable upon sterilization. Autoclavability  was an important consideration, as a preservative-free, single-use BMT-NV- GEL-IM will avoid side- effects associated with repetitive application of  drops containing preservatives like benzalkonium chloride (BAK). An extended  in vitro release of BMT (80.23%) was observed for 10 days while the IOP  lowering effect extended over 2 months with single subconjunctival injection  of BMT-NV-GEL-IM in rats. No clinical signs of irritation, inflammation, or  infection were observed in any injected eye, throughout the study, as also  confirmed by histology. Furthermore, single administration of BMT-NV-GEL as  topical drop lowered the IOP over 5 days. Presence of significant diffuse  fluorescence in confocal microscopy of internal eye tissues post-in vivo  application, as subconjunctival implant, even after 2 month and eye drops  upto1 week provide direct evidence of successful sustained delivery. We thus  provide an improved modality for antiglaucoma medication in patients who are  challenged to adhere to a regimen of daily eye drops.
PB Elsevier
SN 0928-4931
YR 2019
FD 2019-05-10
LK https://hdl.handle.net/20.500.14352/13403
UL https://hdl.handle.net/20.500.14352/13403
LA eng
NO Received 24 October 2018; Received in revised form 7 May 2019; Accepted 7 May 2019; Available online 10 May 2019
NO UGC-RFMS fellowship
DS Docta Complutense
RD 6 may 2024